Navigation Links
Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D
Date:3/5/2012

g Person sent an e-mail to Karen Dawes, Co-Chairperson of the Board of the Issuer.  The contents of the e-mail are attached as Annex A to this Amendment No. 7 to Schedule 13D.

Item 5.
Interest in Securities of the Issuer
is hereby amended and restated in its entirety as follows:(a)
The aggregate number of shares of the Stock owned beneficially by the Reporting Person is 2,815,631 (the "Shares") constituting approximately 9.2% of the outstanding shares of the Stock.
The percentages in this Item  5(a) are based upon 30,714,757 shares of the Issuer's common stock issued and outstanding as of October 31, 2011, as reported on the Issuer's Form 10-Q for the fiscal quarter ended September 30, 2011. 

(b)
The Reporting Person has the sole power (and no shared power) to vote or dispose of or direct the disposition of Shares owned by such Reporting Person.

(c)
During the sixty (60) days prior to the filing of this Amendment to this Schedule 13D, the Reporting Person has made no transactions in the Shares of the Issuer:

(d)
Not applicable.

(e)
Not applicable.

SIGNATUREAfter reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated as of March 5, 2012

 

 

 

___/s/ Barry L. Fischer_______________

Barry L. Fischer,

attorney-in-fact for Ronald L. Chez 

 

 Annex A

March 5, 2012

VIA E-Mail
Karen Dawes
Repligen Corporation

Ms. Dawes:

Thank you for your e-mail of February 27th, where you indicated that you thought we had a constructive discussion in Boston, and indicated that I should submit any director candidates to Repligen's Nominating and Corporate Governance Committee.

I would take issue with regard to the quality of the meeting, considering that I f
'/>"/>

SOURCE Ronald L. Chez, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment
2. SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012
3. GMH Ventures Acquires Majority Ownership in Dynamic Healthcare Services, Leading Provider of Medical Equipment and Respiratory Therapy Products and Services
4. CME LLC Announces the Launch of the CME Activity Advances in the Management of Major Depressive Disorders
5. Brainlab ExacTrac® System Achieves Major Sales Milestone
6. Neuralstems NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
7. Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000
8. Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey
9. Major Israeli Institution Selected to Lead Human Clinical Trials for Revolutionary Alpha Radiation Cancer Therapy
10. Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
11. Scandal Exposed in Major Study of Autism and Mercury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Phase I ... the US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology ... today announces that it has begun a Phase I, ... inhibitor, KVD001, for the treatment of DME. The study,s ... Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical School ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... March 15 Sequenom, Inc. (Nasdaq: SQNM ) today reported its financial results for the fourth quarter and year ended December 31, 2009 . , ... , , ... ...   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ...
... March 15 International Merchant Advisors, ... today that the company has completed the purchase of ... Inc. in an all stock transaction.  Organic Science, Inc. will ... this business segment, and is focused on the ...
Cached Medicine Technology:Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 2Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 3Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 4Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 5Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 6Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 7Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 8Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 9Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 10Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 11Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 12Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 13Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 14Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 15Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 16International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 2International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 3
(Date:8/20/2014)... Rockville Centre, NY (PRWEB) August 20, 2014 ... Martinotti and filed on August 7 in the multicounty ... New Jersey (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; ... in the MCL have been dismissed without prejudice. The ... “in the process of being resolved.” The Rottenstein Law ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... One Call Alert expands its line of personal ... fully-mobile wearable device that connects customers to the help they ... a day, 365 days a year. , ResCube can go ... operates on the T-Mobile nationwide network like a cell phone, ... , Like with the other One Call Alert systems, ResCube ...
(Date:8/20/2014)... Auckland suggest that both major forms of diabetes are the ... today in the FASEB Journal (20 August), provide ... are both caused by the formation of toxic clumps of ... on 20 years, work in New Zealand, suggest that type-1 ... reversed by medicines that stop amylin forming these toxic clumps. ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... May 21, 2012. West Orange, NJ. Scientists at ... studies in multiple sclerosis at the Hilton San Diego ... John DeLuca, Nancy Chiaravalloti and Yael Goverover are addressing ... Multiple Sclerosis Centers (CMSC) and the Americas Committee for ...
... peers and primary care office staff can help patients improve ... new drug, a new study found. Barbara J. Turner, M.D., ... senior author. The randomized, controlled trial examined whether six ... care office staff could benefit African-American patients who had ...
... 21 (HealthDay News) -- Heart damage can be present in obese ... preliminary study found. Obesity is a risk factor for heart ... to their hearts. In the new study, researchers examined the ... overweight and 32 obese -- with no symptoms of heart disease. ...
... General Hospital (MGH) surgeons have developed a new technique ... In the May Annals of Otology, Rhinology ... which uses cryopreserved aortas from deceased donors to replace ... permanent tracheotomy and maintain voice and swallowing function with ...
... May 21 (HealthDay News) -- Having so-called intensivist physicians on ... death rates in ICUs that do not have similar coverage ... An intensivist is a doctor who specializes in the care ... or co-manage patients during the day are referred to as ...
... Almost a century after telephone pioneer Alexander Graham ... vapor sensors ― "electronic noses" ― are being developed ... and other futuristic uses. A new episode in ... series takes viewers on a behind-the-science tour of ...
Cached Medicine News:Health News:Kessler Foundation scientists present cognitive research findings at MS dual symposium 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Obese Teens Can Have Heart Damage Without Showing Signs 2Health News:Donor aortic graft improves reconstruction after partial laryngectomy 2Health News:Night Staffing With Critical Care Docs May Lower ICU Death Rates 2
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
Medicine Products: